ReviewJournal of genetics and genomics = Yi chuan xue bao2020
Engineering T cells for immunotherapy of primary human hepatocellular carcinoma.
Review in Journal of genetics and genomics = Yi chuan xue bao, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 15 citations in OpenAlex.
- MELK prevents radiofrequency ablation-induced immunogenic cell death and antitumor immune response by stabilizing FABP5 in hepatocellular malignancies.Military Medical Research · 2025Article
- Harnessing CD8Clinical and translational medicine · 2024Review
- TCR T cells overexpressing c-Jun have better functionality with improved tumor infiltration and persistence in hepatocellular carcinoma.Frontiers in immunology · 2023Article
- Novel low-avidity glypican-3 specific CARTs resist exhaustion and mediate durable antitumor effects against HCC.Hepatology (Baltimore, Md.) · 2022Article
- Chimeric antigen receptor engineered T cells and their application in the immunotherapy of solid tumours.Expert reviews in molecular medicine · 2022Review
- Mechanism of a Herbal Formula Associated with Prognosis and Immune Infiltration in LIHC: Transcriptomics Analysis and Molecular Dynamics Simulations.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Early diagnosis and therapeutic strategies for hepatocellular carcinoma: From bench to bedside.World journal of gastrointestinal oncology · 2021Review
- Article
- Hepatocellular carcinoma immunotherapy: The impact of epigenetic drugs and the gut microbiome.Liver research (Beijing, China) · 2020Article
- Identification of Driver Genes Regulating the T-Cell-Infiltrating Levels in Hepatocellular Carcinoma.Frontiers in genetics · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Liver cancers, majority of which are primary hepatocellular carcinoma (HCC), continue to be on the rise in the world. Furthermore, due to the lack of effective treatments, liver cancer ranks the 4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.